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NHLAbstract Foxp3 has been studied as a biomarker of Treg cells in many solid malignant diseases,
although its role as an immunomodulator in B-NHL remain poorly understood and the effect of
traditional chemotherapy on its expression remains unclear. In this study the role of circulating
and intra-tumoral Treg and TGF-b in patients with B-NHL before and after chemotherapy was
evaluated. Enumeration of Treg cells was carried out by ﬂow cytometric staining of their cell surface
markers CD4 and CD25 as well as by molecular analysis of its signature transcription factor FoxP3.
Expression of FoxP3 was done using quantitative real-time PCR while TGF-b mRNA expression
was semi-quantitatively assayed by the conventional reverse transcription-PCR. In addition,
spontaneous versus mitogen-induced release of TGF-b by PBMCs was assessed by a short term cell
culture followed by ELISA. This was done before and after six cycles of CHOP chemotherapy. The
results were evaluated in relation to the clinicopathological data.
A signiﬁcant increase in mRNA transcripts of both Fox P3 and TGF-b as well as the percentage of
CD4+/CD25+ in B-NHL patients before receiving the chemotherapy were recorded, when
compared either to healthy controls or to patients after completion the treatment regimen. Interest-
ingly 6 cycles of CHOP treatment caused signiﬁcant reduction in all parameters under study,
254 L.H. El-Sayed et al.relative to the situation before treatment. A signiﬁcant enhancement in spontaneous TGF-b release
in B-NHL patient either before or after chemotherapy was obtained. These results strongly conﬁrm
the possible involvement of Treg cells and TGF-b in orienting the clinical course of the disease as
well as the ability of targeting them in immunotherapeutic approaches.
ª 2013 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
NHL is a heterogeneous group of malignancies involving
uncontrolled clonal expansion of transformed B or T cells in
the periphery. In Egypt, the incidence of NHLs is very high.
According to Middle East Cancer consortium (MECC), the
NHLs age standardized incidence rates (ASRs) are (16.3/
100.000 person). This very high incidencemakesNHLs the third
most common cancer in Egyptian males and the second most
common cancer in females as reported byNational Cancer Insti-
tute (NCI) accounting for 10.9% of all cancers in Egypt diag-
nosed every year.1,2 The incidence of NHL has increased
during the past several decades at an average rate of 3–4% per
year.Most of this increase can be attributed to a rising incidence
of mature B-NHL, which represent about 90% of all NHL
cases.3 The clinical course of this disease is variable and the
molecular and cellular mechanisms responsible for the clinical
heterogeneity of B cell NHL are largely unknown. Although
many therapeutic regimens have been developed for B-NHL,
many of them remain incurable with frequent relapse/remission
cycles4 De Jong et al., (2005)5 showed that the complex intrac-
tions between the neoplastic B cells and the surrounding micro-
environment plays an important role in disease severity and
clinical outcome as well as response to therapy. More recently,
analysis of gene expression using microships in follicular and
diffuse B cell lymphomas have indicated that the nature of
non malignant lymphocytes within the affected lymphomas is
of considerable prognostic importance.6 Peripherally induced
Treg cells play an important role in suppressing the antitumor
immune response particularly within the tumor microenviron-
ments where increased Treg cell frequencies and function might
favour tumor development and growth interfering with CD8+
T cell-mediated immunity and subsequently, inﬂuencing the
course of the disease.7 Meanwhile, the mechanisms and the sig-
nal pathways by which TGF-b generates and expands these
diverse Treg subsets remain largely unknown.8,9 It is now largely
accepted that manipulation of Treg cells either by chemo- or
immunotherapeutic regimens might represent a promising
approach in the ﬁeld of cancer management.102. Aim and Methods
The present study aimed at assessment of peripheral and intra-
tumoral Treg populations in Egyptian patients diagnosed as
B-NHL either before or after deﬁned cycles of chemotherapy
in order to elucidate their possible role in orienting the clinical
course of the disease as well as the possibility of targeting them
in future prospects of antitumor approaches. Methodology
Subjects: The study was carried out on 25 patients with
B-NHL recruited from the Clinical Oncology Department at
Medical Research Institute, Alexandria University (at year2009 and follow up till 2011) in addition to 10 normal healthy
age- and sex-matched individuals as controls. Following surgi-
cal excision and histopathological diagnosis, B-NHL patients
received 4–6 cycles of CHOP as a selected therapeutic regimen,
at 21 days intervals. Criteria for positive selection
 Histologically proven B-NHL.11
 Intermediate grade based on working formulation system.
 Performance status 0 and 1 based on Eastern Cooperative
Oncology Group (ECOG) scale.12
 Adequate kidney, liver and cardiac functions.
All patients in the study were subjected to the following
(1) Full history taking with special reference to personal his-
tory of solid or hematological malignancies.
(2) Thorough clinical examination with special reference to
pan or localized lymph node enlargement.
(3) Laboratory investigations including CBC, LDH, liver
and kidney function tests.
(4) Radiological investigations including CT chest, CT or
U/S abdomen and pelvis.
(5) Cardiac assessment by echocardiography.
(6) Follow up of the patients was carried out by radiological
and laboratory investigations as well as clinical exami-
nation every 3 months in the ﬁrst year after the end of
treatment and every 6 months in the second year.
Methodology
 Excisional lymph node biopsy
Following surgical excision of suspected lymph nodes, they
were immediately preserved in a solution of 10% buffered for-
maline for routine histopathological assessment and for molec-
ular veriﬁcation of both FoxP3 and TGF-b.
 Blood sampling
Approximately 5 ml of heparinised peripheral blood were
obtained from all the subjects under study by vein puncture
and used for total RNA extraction.
From all B-NHL patients (either before or after chemother-
apy) as well as from normal healthy controls, PBMCs were
isolated by density gradient centrifugation over Ficoll-
Histopaque and were subjected to a short-term culture either
in the presence or absence of PHA mitogenic stimulation. Cul-
ture supernatents were harvested and assayed for TGF-b
release by ELISA. PBMCs were also used as a starting mate-
rial for phenotypic analysis of CD4/CD25 double positive cells
by ﬂow cytometry. Furthermore, RNA extracted out of
PBMCs was also used to study the expression of both
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TGF-b expression was also assayed in the tumor microenvi-
ronment in RNA extracts of excised lymph nodes by PCR.
2.1. Immunological studies
Separation of peripheral blood mononuclear cells by density gra-
dient centrifugation over Ficoll-Histopaque, according to the
method adopted by Boyum (1986).13
(A) Assessment of TGF-b release by PBMCDetails of the
tissue culture assay were adopted from the original
method described by Lederman et al., (1998).
14
TGF-b
levels in the culture suppernatents of all samples, with-
out and with PHA supplementation were determined
using a quantitative enzyme- linked immunosorbant
assay ‘‘ELISA kit.’’ Bender MedSystems GmbHH,
Campus Vienna.15
(B) Enumeration of Treg (CD4 + CD25+) by ﬂow cytom-
etryThis was done by a ﬂow cytometric enumeration of
both of them using relevant ﬂuorescen and phycoery-
thrin-labelled monoclonal antibodies according to the
method of Vaickus et al., (1991).16
2.2. Molecular studies
The present study involves molecular detection of mRNA of
both Foxp3 and TGF-b in PBMCs and L.N extracts by
PCR technique using quantative (real-time) PCR and conven-
tional PCR respectively before and after chemotherapy.
(a) RNA extraction from PBMCsTotal RNA was prepared
from fresh PBMCs isolated from all subjects under
study. This was done adopting the method described
by n Boom et al., (1990)17 and using speciﬁc columns
and kits commercially available from Qiagen, USA.
All extraction steps were carried out at room tempera-
ture under strictly aseptic conditions.
(b) RNA extraction from parafﬁn-blocked LNTotal cellular
RNAwas extracted fromparafﬁn blocks ofB-NHL tissues
with Trizol reagents according to the guidelines provided
by Rupp et al., (1988)18 under strictly sterile conditions
in a biosafety cabinet, under RNAse-free conditions.
(c) Assessment of RNA integrity and PurityThemost common
method used to assess the integrity of total RNA is to run a
sample of 5 ll of the extracted RNA on 1.5% agarose gel
electrophoresis with 0.5· TBE buffer followed by staining
with ethidium bromide.19 The purity of extracted RNA
was tested by 260/280 spectrophotometric analysis.20
(d) Reverse transcription of RNAAll RNA extracts pre-
pared either from PBMCs or LNs were immediately
used as templates for preparation of respective comple-
mentary DNA sequences. According to Berchtold
(1989)21 using Gene Amp RT-PCR System (Gene).
The obtained cDNA was used for the second ampliﬁca-
tion of the Foxp3 gene using the speciﬁc forward and
reverse primers as well as speciﬁc probes.22,23
(e) Foxp3 ampliﬁcation in PBMCs and LN by real time
PCRFoxp3 and GADPH speciﬁc primers and probes
employed in real time PCR.Foxp3 Primers
Forward GGCCCTTCTCCAGGACAGA
Reverse GCTGATCATGGCTGGGTTGT
Taqman probe 5-6- FAM-ACTTCATGCATCAGCTCTCCA
CTGTGGAT-BHQ-1-3
GADPH primers
Forward GCCATCAAAGAAGCCCTGAA
Reverse GCGGGTCTGCACACATGTTA
Taqman probe TPACATGCCTGTCACATTGAATGAAGA
GGTAGAAGRelative quantiﬁcation (RQ) of the real time-PCR data was
done according to the following equation.
RQ = Ct target gene/Ct reference (housekeeping) gene.
Copy number = 2DCt where DCt is the calculated normal-
ized Ct.
(a) Qualitative PCR detection of TGF-b geneThe TGF-b
gene was qualitatively monitored by standard PCR As
described by Kufer et al., (2002).24
Foxp3 Primers
Forward GAACCCAATGCCAACCCTAG
Reverse TTCTTGGTTTTGAGGTCAAGG2.3. Statistical analysis
The statistical and graphical analysis of the results were carried
out using statistical package for the social sciences (SPSS) ver-
sion 10.0 Student’s t test was used to analyze the obtained
data, the differences between groups and the correlation
between all the measured parameters. P< 0.05 was considered
statistically signiﬁcant. The actuarial survival analysis was per-
formed according to the method described by Kaplan and
Meier.3. Results
3.1. Study population
The present study was conducted on a total of 35 individuals;
including 25 B-NHL patients diagnosed according to the
results of histopathological and immunohistochemical assess-
ment of surgically excised lymph nodes. They received 4–6
cycles of CHOP as a selected chemotherapy regimen. In addi-
tion, 10 healthy age- and sex-matched individuals were
included in the study as negative controls.
Table 1 illustrates the clinicopathological characteristics of
our patients. They included 15 males and 10 females with
male/female ratio of 3:2 having age range of 45–60 years with
a mean ± S.D of 48.38 ± 5.65. The frequency of major path-
ological types encountered as well as the performance status of
the patients and clinical stage. According to this table, 15/25
(60%) of the involved patients had B-NHL of small follicular
Table 1 Clinico-pathological characteristics of B-NHL patients.
Demographic data Healthy controls B-NHL patients P
Age – – 0.41
Range 46–60 45–60 –
Mean±SD 49.74 ± 6.2 48.38 ± 5.65 –
No. % No. % –
Sex – – – – –
Male 6 60 30 60 –
Female 4 40 20 40
Pathological type of B-NHL – – – –
Small follicular – – 30 60 –
Large diﬀuse – – 20 40
Stage
I – – 0 0.0 –
II s- – 10 20.0 –
III – – 24 48.0 –
IV – – 16 32.0 –
256 L.H. El-Sayed et al.type, while 10/25 (40%) were diagnosed as B-NHL of the large
diffuse type. Concerning tumor grade, the study was done only
on those diagnosed as grade II B-NHL while other grades were
omitted from the study.3.2. Routine laboratory ﬁndings
Investigationswere performed for all patients before starting the
recommendedCHOP treatment, regularly before each cycle and
at the end of treatment cycles. This was done in order tomonitor
the effects of chemotherapy on liver and kidney functions aswell
as haemoglobin level. Only results obtained before starting
treatment and those recorded at the end of chemotherapy are
concerned and summarized in (Table 2). Statistical analysis of
these data showed that signiﬁcant variations were observed.Lactate dehydrogenase (LDH)
As an important conventional prognostic marker for NHL, all
patients were further assayed for serum LDH before startingTable 2 Statistical comparison of hemoglobin, liver and kidney
chemotherapy.
Laboratory investigations B-NHL patients before treatment
Hemoglobin (g/dL)
Range 9.5–12.2
Mean±SD 10.72 ± 0.83
SGOT (U/L)
Range 14–37
Mean±SD 27.71 ± 6.70
SGPT (U/L)
Range 13–38
Mean±SD 23.63 ± 5.99
Urea (mg/dL)
Range 20–49
Mean±SD 32.33 ± 7.70
Creatinine (mg/dL)
Range 0.37–1.1
Mean±SD 0.78 ± 0.23
LDH (U/L)
Range 250–480
Mean ± SD 328.52 ± 59.768
* P is signiﬁcant if <0.05.and after completion of therapeutic CHOP regimen. Statistical
analysis of the obtained data showed that a signiﬁcant reduc-
tion was recorded in serum LDH level of B-NHL patients at
the end of CHOP treatment as compared to that registered
before chemotherapy (Fig. 1).
3.3. Immunological ﬁndings
3.3.1. Spontaneous and activation-induced release of TGF-b
(pg/ml)
Spontaneous TGF-b release from PBMCs in healthy controls
had a mean ± S.D of 0.027 ± 0.011 compared to
0.125 ± 0.102 and 0.182 ± 0.137 in B-NHL patients either be-
fore or after CHOP treatment respectively. Statistical analysis
of these results revealed a signiﬁcant enhancement in spontane-
ous TGF-b release by PBMCs of B-NHL patients when com-
pared to healthy controls (p= 0.0136 and 0.032 respectively).
However, no signiﬁcant difference was recorded upon compar-
ing basal TGF-b release by PBMCs of B-NHL patients before
and after chemotherapy (p= 0.147) (see Table 3).function tests in B-NHL patients before and after CHOP
B-NHL patients after treatment Test of signiﬁcance (p)
0.001*
10.2–13
11.46 ± 0.85
0.0109*
19–65
33.04 ± 9.03
0.002*
20–37
29.08 ± 5.55
0.0337*
20–49
36.84 ± 8.83
0.025*
0.63–1.21
0.89 ± 0.19
0.042*
245–421
310 ± 48.70
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Figure 1 Diagrammatic illustration of serum LDH results
(Units/L) of B-NHL patients before and after CHOP
chemotherapy.
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0.259 ± 0.282 pg/ml was recorded in healthy controls com-
pared to 0.094 ± 0.113 pg/ml and 0.236 ± 0.186 in B-NHL
patients before and after chemotherapy respectively (Table 4).
Statistical analysis of these data showed a remarkable impair-
ment in PHA-induced TGF-b release by PBMCs from B-NHL
as shown in Fig. 2.
3.3.2. TGF-beta expression in PBMCs
The RT-PCR results of PBMCs mRNA expression of TGF-b
are semi-quantitatively expressed as a relative index denoting
the ratio between TGF-b expression to that of a housekeeping
gene (b-actin) (see Fig. 3). Results are summarized in Table 5
and are represented in Fig. 4. According to the obtained data,
statistical analysis revealed that there was a signiﬁcant eleva-
tion in TGF-b mRNA expression in PBMCs of B-NHL
patients either before or after treatment as compared to
healthy controls (p< 0.001). In addition, there was a signiﬁ-
cant reduction in spontaneous mRNA expression of TGF-b
in B-NHL patients by the end of the CHOP therapy in com-
parison to records obtained before treatment (P< 0.001).
3.3.3. Enumeration of peripheral blood CD4 and CD25
Peripheral blood detection of CD4 and CD25 was done for all
subjects under study by ﬂow cytometry using relevant mono-
clonal antibodies and results are expressed as percentage of
double positive cells and are summarized in Table 6, Fig. 5Table 3 TGF-b spontaneous release (pg/ml) by PBMCs.
Basal TGF-b release (pg/ml) Healthy controls B-NHL
Range 0.021–0.055 0.019–0
Mean ± SD 0.27 ± 0.011 0.125 ±
p1 – 0.0136*
p2 – –
* P is signiﬁcant if <0.05.the mean ± S.D of CD4+ cells in healthy controls was
36.04 ± 12.84 compared to 31.21 ± 7.33 and 34.9 ± 4.31 in
B-NHL patients before and after CHOP treatment respec-
tively. CD25+ cells of healthy individuals had a mean ± S.D
of 14.9 ± 2.28 relative to 24.8 ± 5.07 and 24.4 ± 7.07 in B-
NHL patients before and after chemotherapy respectively.
Concerning CD4/CD25 double positive cells, the mean ± S.D
of healthy controls was 10.9 ± 2.38 in comparison with
25.2 ± 6.27 and 16.3 ± 2.06 in B-NHL patients before and
after treatment respectively. Table 6 and Fig. 5.3.3.4. Foxp3 expression in PBMCs
The real-time PCR results of Foxp3 expression in RNA
extracts of PBMCs are expressed as relative index. Statistical
analysis of these results point out to a signiﬁcant increase in
mRNA transcripts of Foxp3 in B-NHL patients before receiv-
ing CHOP treatment when compared either to healthy controls
(p= 0.03) or to patients after completion of treatment
(p= 0.05, Table 7 and Fig. 6).3.3.5. TGF-beta and Foxp3 expression in lymph nodes
Results are summarized in Table 8. Statistical analysis of the
results shows that neither of the clinico-pathological parame-
ters had signiﬁcant effect on the intratumoral mRNA expres-
sion of TGF-b while that of Foxp3 was positively inﬂuenced
by higher age (P< 0.001), male gender (p= 0.004), high
serum LDH level (p= 0.003) and follicular type of affected
lymph nodes (p= 0.039).
Correlation analysis and the outcome of the patients
The median follow up of our patients was 24 months, pro-
gression, relapse, or death were observed in the studied
patients. The overall survival (OS) was deﬁned as the interval
from date of diagnosis until death from any cause. Progres-
sion-free survival (PFS) was deﬁned as the interval between
diagnosis and progression of lymphoma or death due to lym-
phoma or toxicity of treatment. (Tables 9 and 10 and Figs. 7
and 8) represents the overall survival and the progression free
survival of our patients which were 84% and 40% respectively
at the event end point.
The response to treatment was assessed according to con-
ventional criteria, 25 among the 25 patients 24% achieved
complete response (CR)and 28% partial response, whereas
24% failed to respond to treatment.(Table 11).
Pearson correlation analysis (2-tailed) were performed
between different parameters in all patients under study.
Results are summarized in Table 12 revealed the following:
(1) Signiﬁcant positive correlation between serum LDH and
of peripheral blood CD4/CD25 double positive pheno-
type (r= 0.494, p< 0.001).patients before treatment B-NHL patients after treatment
.313 0.022–0.539
0.102 0.112 ± 0.114
0.032*
0.147
He
al
th
yc
on
tro
ls
Pa
tie
nt
s
be
fo
re
tre
at
m
en
t
Pa
tie
nt
s
af
te
r
tre
at
m
en
t0
0.05
0.1
0.15
0.2
0.25
0.3
PH
Ai
nd
uc
ed
TG
F-
β(p
g/
m
l)
B-NHL 
patients 
*
*
Figure 2 Diagrammatic representation of PHA induced TGF-b
results (pg/ml).
Table 4 Statistical analysis of the results of PHA induced TGF-b release (pg/ml) by PBMCs of healthy controls as compared to
B-NHL patient either before or after CHOP treatment.
PHA-induced TGF-b release (pg/ml) Healthy controls B-NHL patients before treatment B-NHL patients after treatment
Range 0.018–0.611 0.020–0.388 0.031–0.584
Mean ± SD 0.259 ± 0.282 0.094 ± 0.113 0.236 ± 0.186
p1 – 0.0218* –
p2 – 0.547
– 0.024*
* P is signiﬁcant if <0.05.
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Figure 3 Diagrammatic representation of basal TGF-b sponta-
neous release (pg/ml).
258 L.H. El-Sayed et al.(2) Signiﬁcant positive correlation between peripheral blood
Foxp3 expression and percentage of peripheral blood
CD4/CD25 double positive phenotype (r= 0.319,
p= 0.013).
(3) Signiﬁcant positive correlation between peripheral blood
Foxp3 expression and the performance status of the
patients as well as the stage of the disease.
(4) Signiﬁcant positive correlation between peripheral blood
mRNA expression of TGF-b and CD4/CD25 double
positive phenotype (r= 0.509, p=<0.001).(5) Signiﬁcant positive correlation between peripheral blood
TGF-b expression and the performance status of the
patients as well as the stage of the disease.
4. Discussion
NHL is a heterogeneous group of malignancies involving
uncontrolled clonal expansion of transformed B or T cells in
the periphery. The incidence of NHL has increased during
the past several decades in the United States at an average rate
of 3–4% per year. Most of this increase can be attributed to
arising incidence of mature B-NHL, which represent about
90% of all NHL cases.3
The most common B-cell lymphoma subtypes include fol-
licular lymphoma, diffuse large B-cell lymphoma, marginal
zone lymphoma and mantle cell lymphoma.26 The clinical
course of this disease is variable and the molecular and cellular
mechanisms responsible for the clinical heterogeneity of B cell
NHL are largely unknown. Although many therapeutic regi-
mens have been developed for B-NHL, many of them remain
incurable with frequent relapse/remission cycles.4 Malignant B
cells develop in specialized tissue microenvironments that are
characterized by different populations of stromal cells and var-
ious subsets of T cells, including CTL and regulatory T-cells.
These cells interact with malignant blood cells with variable
degrees of dependency on signals from the microenvironment
that involves number of immunologic molecules as chemo-
kines, adhesion molecules and cytokines.27
De Jong et al., (2005)5 showed that the complex interac-
tions between the neoplastic B cells and the surrounding
microenvironment plays an important role in disease severity
and clinical outcome as well as response to therapy. More
recently, analysis of gene expression using microchips in follic-
ular and diffuse B-cell lymphomas have indicated that the nat-
ure of non malignant lymphocytes within the affected
lymphomas is of considerable prognostic importance.6 In the
present study, serum levels of LDH were monitored as a piv-
otal serological marker of all haematological malignancies
including lymphomas. According to our results, 14 out of 25
(56%) of B-NHL patients enrolled in the study at the time
of diagnosis had serum LDH levels exceeding 460 U/L. At
the end of CHOP treatment on the other hand, neither of
the examined cases had serum LDH levels above the reference
range. Statistical analysis of these results showed a mildly sig-
niﬁcant reduction in serum LDH at the end of CHOP chemo-
therapy relative to that recorded before treatment. This ﬁnding
is enforced by a recent observation by Mazhar et al., (2010)28
who showed that LDH level was signiﬁcantly raised in NHL
Table 5 mRNA expressionof TGF-b (relative index) in PBMCs from B-NHL patients.
TGF-b (relative index) Healthy controls B-NHL patients before CHOP therapy B-NHL-patients after CHOP therapy
Range 0.5–2.5* 5–25 5–15
Mean 1.33 15.33 9.67
S.D. 0.61 6.40 3.52
–
P1 – <0.001* <0.001*
P2 – – <0.001*
* P is signiﬁcant if <0.05.
TGF-β (300 bp)
β-Actin (154 bp)
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Figure 4 PCR product analysis on agarose gel electrophoresis (2%). Lane (1) DNA ladder (50 bp), Lanes (2 and 3) b actin gene, Lanes
(4–7): TGF-b from a L.N extract, PBMCs of a B-NHL patients after chemotherapy, a patient before chemotherapy and a healthy donor.
Table 6 Statistical comparison of CD4+, CD25+ and CD4+/CD25+ double positive cells amonghealthy donors as compared to
B-NHL patients before and after CHOP treatment.
Flow cytometric stain Healthy controls B-NHLpatients before treatment B-NHL patients after treatment
CD4+ cells (%) – – –
Range 21–58 20–37 26–40
Mean±SD 36.40 ± 12.84 31.20 ± 7.33 34.90 ± 4.31
Test of signiﬁcance (p) – 0.140 0.365
– – 0.093
CD25+ cells (%) – – –
Range 11–18 13–30 15–35
Mean±SD 14.90 ± 2.28 24.80±5.07 24.40 ± 7.07
Test of signiﬁcance (P) – 0.004* <0.001*
CD4/CD25double positive cells (%) – 0.451
Range 7–14 20–35 13–19
Mean±SD 10.90 ± 2.38 25.20 ± 6.27 16.30 ± 2.06
Test of signiﬁcance (P) – <0.001* <0.001*
– <0.001*
* P is signiﬁcant if <0.05.
Prognostic value of FOXP3 and TGF-b expression in both peripheral blood and lymph nodes in patients 259patients and is positively inﬂuenced in patients with bone mar-
row inﬁltration than those without. They concluded that this
non-invasive parameter is a useful indicator of the extent of
the disease (see Table 13).Moreover, Yang et al., (2009) 29 studied the clinical signif-
icance of serum LDH in NHL patients and showed that it was
correlated positively, together with b2 microglobulin, to the
advancement of the disease since both parameters were higher
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Figure 5 Diagrammatic representation of the results of PBMC
mRNA expression of TGF-b (relative index).
260 L.H. El-Sayed et al.in patients with late stage NHL having B symptoms and bone
marrow involvement. They found also that this marker was
obviously lower in responders than non-responders to chemo-
therapy. Interestingly, the same authors proved that neither
age nor gender of patients inﬂuenced serum level of LDH.
In the current work, we investigated the gene expression of
Foxp3 and TGF-b in nodal RNA extracts of B-NHL patients.
The results of such an intratumoral expression of both markers
were sorted out according to some of the available clinicopath-
ological parameters of NHL including patient‘s age, gender,
serum LDH and tumor type. The results revealed thatTable 7 Statistical comparison between the expression of Foxp3 (r
(either before or after treatment) as compared to their correspondin
Foxp3 (relative index) Healthy controls B-NHL p
Range 0.8–1.19 1.08–1.21
Mean 1.05 1.13
SD 0.12 0.04
Test of signiﬁcance (P) – 0.030*
– –
* P is signiﬁcant if <0.05.
(a) From B-NHL patients before 
chemotherapy
Figure 6 Flow cytometric dot plots showing two colour hisexpression of Foxp3, but not TGF-b, was signiﬁcantly higher
in males, older age, elevated serum LDH and follicular
lymphomas than their corresponding partners. This ﬁnding
was in accordance with Zhi-Zhang et al., (2006)30 who com-
pared Foxp3 expression in nodal versus extra-nodal RNA
extracts and showed that lymph node-derived Foxp3 expres-
sion was higher than that of peripheral blood, non-malignant
tonsils, spleens and others.
These results were even reproducible when repeatedly inves-
tigated more recently by Lin et al., (2009).31 They stated that
NHL is generally a disease with higher male than female and
older than younger age prevalence. However, the mechanism
underlying this higher male incidence of the disease remains
speculative and needs further investigation. The same authors
claimed also that peripheral blood Treg level was not signiﬁ-
cantly correlated to other clinical features of NHL and attrib-
uted this ﬁnding to the fact that immune suppression by Treg
had certain role in the occurrence of lymphomas but might not
be related to subsequent tumor advancement once the disease
is established.
In addition, Laurenti et al., (2011)32 found that T reg pop-
ulation was correlated to the LDH level where increased T reg
percentage was associated with elevated serum LDH. It would
be convincing that Foxp3 expression in LDH-high group of B-
NHL patients was higher than that of LDH-normal group
since elevated serum levels of LDH might reﬂect more
aggressive forms of the disease and it constitutes a putative
component of the complex international prognostic index of
all haematological malignancies including, in particular,
B-NHL.33elative index) in RNA extracts of PBMCs from B-NHL patients
g healthy controls.
atients before treatment B-NHL Patients after treatment
0.6–1.19
1.04
0.16
0.419
0.05*
(b) From B-NHL patients after
 chemotherapy
togram (FSC-H/SSC-H) of PBLs from B-NHL patients.
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Figure 7 Kaplan Mayer curve for over all survival of B-NHL.
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Figure 8 Kaplan Mayer curve for progression free survival.
Table 8 Statistical analysis of intratumoral mRNA expression of Foxp3 and TGF-b (relative index) distributed according to patient‘s
age, sex, gender and serum LDH level.
Parameter Foxp3 (mean ± SD) Test of signiﬁcance (p) TGF-b (mean ± SD) Test of signiﬁcance (p)
Patient’s age
>50 years 1.20 ± 0.04 0.001* 16.54 ± 5.91 0.196
<50 years 1.15 ± 0.04 14.17 ± 7.64
Patient’s sex
Male 1.18 ± 0.04 0.03* 16.818 ± 6.809 0.18
Female 1.13 ± 0.04 14.286 ± 6.753
Serum LDH
>460 1.161 ± 0.05 0.03* 16.818 ± 6.809 0.18
<460 1.155 ± 0.05 14.286 ± 6.753
Pathological type 1.17 ± 0.04 0.0039* 17.50 ± 7.91 0.238
Follicular diﬀuse 1.13 ± 0.04 15.33 ± 6.94
* P is signiﬁcant if <0.05.
Table 9 Distribution of the studied patients regarding the
outcome.
Response No. of the patients Percent
Complete response 40 80.0%
Partial response 10 20.0%
Table 10 Overall survival of B-NHL patients all over the
period of follow up.
Duration /Month No. of the patients %
At base line 50 100.0
6 months 48 96.0
12 months 46 92.0
18 months 44 88.0
24 months 42 84.0
Table 11 Progression free survival of the studied patients all
over the period of follow up.
Duration/month No. %
At base line 50 100.0
6 months 36 72.0
12 months 24 48.0
18 months 22 44.0
24 months 20 40.0
Prognostic value of FOXP3 and TGF-b expression in both peripheral blood and lymph nodes in patients 261In the present study, peripheral blood genetic expression of
Foxp3 and TGF-bwas assessed by PCR in parallel to ﬂow cyto-
metric enumeration of peripheral CD4/CD25 double positivecells. These parameters were taken as characteristic markers
for assessment of the proportion of peripheral Treg populations.
Our study showed that the peripheral blood mRNA expression
ofTGF-b andFoxp3was signiﬁcantly higher inB-NHLpatients
relative to healthy controls. This was accompanied by increased
percentage of CD4/CD25 double positive cells in peripheral
blood of B-NHL patients (25%) as compared to healthy con-
trols (10.9%). The abovementioned results point out to a signif-
icant enhancement of Treg cell frequencies in B-NHL patients
relative to their corresponding healthy subjects.
Table 12 Relation between response and over all survive in relation to both Foxp3 and TGF-b.
Response P Over all survive p
Complete ‘‘n= 40’’ Partial ‘‘n= 10’’ Survive ‘‘n= 42’’ Die ‘‘n= 8’’
No. % No. % No. % No. %
TGF-B (pg/ml) 0.032* 0.0422*
<15 (n= 32) 31 96.9 1 3.1 29 90.6 3 9.4
>15 (n= 18) 9 50.0 9 50.0 13 72.2 5 27.8
Foxp3 (relative expression)
<1.1 (n= 21) 19 90.5 2 9.5 0.041* 17 81.0 4 19.0 0.322
>1.1 (n= 29) 21 72.4 8 27.6 25 86.2 4 13.8
262 L.H. El-Sayed et al.These ﬁndings are in agreement with Mittal (2008)33 who
demonstrated that Treg populations in PBMCs of NHL
patients were signiﬁcantly higher than controls and were signif-
icantly correlated with both disease stage and serum LDH
level. In addition, Liu et al., (2006)34 studied the peripheral
blood expression of Treg in B-NHL and proved that the per-
centage of this suppressive subset of T cells was signiﬁcantly
higher than controls. They concluded that the relative increase
of CD4+/CD25high Treg cells in peripheral blood of B-NHL
patients may be independently related to both the state of
immune suppression and tumor progression.
In haematological malignancies other than NHL, Laurenti
et al., (2011)32 found that Treg population was also expanded
in CLL patients compared to controls and was also positively
correlated to speciﬁc markers of disease status. Also, Schmitt
et al., (2008)35 found that B-CLL patients have peripheral
blood Treg percentage higher than healthy volunteers and fur-
ther increased with progression of the disease. In the present
study, the role of TGF-b in modulating peripheral Treg popu-
lation and inﬂuencing the outcome of B-NHL was further
assessed by comparison of the spontaneous versus activation-
induced release of this cytokine following a short term culture
of PBMCs. The results revealed that, similar to mRNA expres-
sion, the spontaneous release of TGF-b by PBMCs from
B-NHL patients was signiﬁcantly higher than that of healthy
controls. Surprisingly, upon polyclonal T cell activation by
PHA mitogen, cells of B-NHL patients were renderedTable 13 Correlation study of different parameters.
Parameter LDH Foxp3
Foxp3 Pearson Correlation .233
p .104
CD4+ Pearson Correlation .347* .706**
p .014 .000
CD25+ Pearson Correlation .009 .619**
p .950 .000
CD4/CD25DP Pearson Correlation .494* .319*
p .000 .013
TGF-b Pearson Correlation .180 .130
p .341 .423
Performa-nce status Pearson Correlation 0.382* 0.398*
p 0.016 0.01
Stage Pearson Correlation 0.425* 0.356*
0.001 0.004
* P is signiﬁcant if <0.05.non-responders when compared to cells of healthy donors.
In fact, it remains unclear if the non-responsiveness of PBMCs
from B-NHL patients represents a manifestation for the gener-
alized state of immune suppression accompanying late stages
of malignancy or simply due to accelerated rates of pro-
grammed cell death following in vitro mitogenic activation of
B-NHL cells relative to those from healthy controls.
It has been suggested that the increased spontaneous release
of TGF-b in B-NHL patients might be attributed to the
enhanced mRNA expression for the same cytokine together
with Foxp3 and CD4/CD25 double positive cells denoting
enhanced peripheral blood Treg population. In accordance
with this explanation, Fu et al., (2004)36,37 found that TGF-
b is a key regulator of the signaling pathways that initiate
and maintain Foxp3 expression and suppressive function in
CD4 + CD25 precursors.
CHOP treatment has been selected as the regimen of choice
on the basis that it is one of the most commonly adopted reg-
imens for the majority of different subtypes of B-NHL. In
addition, it is one of the ﬁrst generation of combination treat-
ments that may be given alone or together with monoclonal
antibodies.38,39 After a median of 2 years of follow up, the
overall survival of the studied group was 84% while the pro-
gression free survival was 40% and only 24% of our patients
showed complete response. in accordance with our study,
Sonneveld et al. (1995)40, demonstrated that inspite that
CHOP regimen is the standard treatment for younger andCD4 CD25 DP TGF-B Performance status
.446**
.000
.443** .267*
.000 .039
.022 .235 .509**
.893 .145 .001
0.107 0.201 0.207 0.103
0.336 0.165 0.177 0.336
0.252* 0.301* 0.485* 0.446** 0.369*
0.048 0.036 0.001 0.001 0.021
Prognostic value of FOXP3 and TGF-b expression in both peripheral blood and lymph nodes in patients 263elderly patients with diffuse large –B- cell lymphoma, but it
induces complete responses in only 40–50% of elderly patients,
with three-year event free and overall survival rates of 30%
and 35–40%, respectively.
According to the plan of the present work, all B-NHL
patients enrolled in the study received CHOP chemotherapy
in the form of 4–6 cycles at 21 days intervals and were assessed
at the end of chemotherapy for the characteristic surface mark-
ers of Treg cells Foxp3 and CD4/CD25 positivity.
According to the obtained results, the peripheral blood per-
centage of CD4/CD25 double positive cells showed signiﬁcant
reduction as compared to the situation before chemotherapy.
This was coincident with a similar reduction in mRNA expres-
sion of Foxp3 and TGF-b by PBMCs. Concerning the results
of basal TGF-b release, it was shown that although a slight
and insigniﬁcant decrease was recorded upon comparison with
patients before treatment, it was still signiﬁcantly higher than
that of healthy subjects. Regarding mitogen-induced release
of TGF-b, our results revealed that PBMCs of B-NHL patients
after treatment almost retained the normal synthetic rate of
this cytokine recorded before the start of chemotherapy.
This package of ﬁndings denotes a signiﬁcant depletion of
the elevated frequency of Treg cells that was recorded in B-
NHL patients at the time of diagnosis. In fact, most of the
immunomodulatory properties of CHOP combination of che-
motherapy might be attributed to cyclophosphamide since
Ghiringhelli et al., (2007)41 observed that small repeated doses
of metronomic cyclophosphamide in patients with different
types of malignancies caused a reduction in the peripheral
blood proportion of Treg cells (assessed by the percentage pos-
itivity of CD4/CD25high cells. This was associated with
improved clinical manifestations and ameliorated overall sur-
vival rate of patients. In addition, Ladoire et al., (2009)42
showed that a combination neoadjuvant chemotherapy con-
taining both adriamycin and cyclophosphamide was effective
in depleting Foxp3+ Treg cell inﬁltrates in tumor tissue in
patients with breast cancer and this was associated with better
improvement in patients with bad prognostic markers such as
nodal affection and ER-/PR-phenotyping.
Zhang et al., (2008)43 hypothesized that the use of chemo-
therapy, although known for its cytotoxic effect, may also ben-
eﬁt immunotherapy by preferential impairment of Treg cells.
As a clinical evidence for this hypothesis, Lissoni et al.,
(2009)44 demonstrated that cancer patients receiving a combi-
nation of chemo and immunotherapy manifested a signiﬁcant
decrease in Treg cells, enhanced anti-tumor immunity and
improved therapeutic outcome compared to those receiving
chemotherapy or radiotherapy but not immunotherapy. This
ﬁnding seems of special interest since the traditional thought
in this context is that chemotherapy adversely affects anti-
tumor immunity by depleting immune cells and subsequently
antagonizing tumor immunotherapy. However, the mecha-
nisms by which the use of chemotherapy paradoxically beneﬁts
immunotherapy await profound elucidation.
More recently, Reeder and Ansell (2010)45 investigated the
possibility of using a fusion protein composed of IL-2
sequence and active fragments of diphtheria toxin (Dd) in
treatment of aggressive B-NHL subtypes. They claimed that
since CD25+ naturally occurring Treg cells are highly
expressed in B cell lymphoma and suppress other intratumoral
immune cells, the use of Dd to deplete Treg cells may be of
clinical beneﬁt. Interestingly, they found good response in bothCD25 positive and negative B-NHL tumors suggesting an off-
target effect for the drug.
Wu et al., (2011)46 showed also that targeting Treg by an
alternative drug between cycles of chemotherapy in a murine
mesothelioma model almost completely depleted T reg cells
and could improve the outcome of the disease.
On the contrary, Shi et al., (2004)47 and Liu et al.,
(2006)34 showed that peripheral blood CD4CD25 Treg cells
were elevated following chemotherapy in B-NHL patients.
Although contradictory to our ﬁndings, these conﬂicting
results might be explained by ethnic variations between
study populations in addition to variations in the stage of
the disease, pathological type and schedule of chemotherapy
as well as time of follow up after treatment. In addition, the
state of Foxp3 expression was not addressed by both articles
rendering their conclusion about Treg population incomplete
and, subsequently, lack further experimental and clinical
evidence.
In addition to possible induction and expansion of Treg
phenotyping by malignant B-NHL cells, recruitment of these
cell populations by lymphoma cells is another mechanism for
increased intratumoral frequency of T reg. This mechanism
was supported by Yang et al., (2006)29, who investigated the
expression of Treg cells in B-NHL and found that intratumor-
al Treg cells expressed CCR4 while lymphoma B cells
expressed CCL22. They concluded that CCR4+ intratumoral
Treg cells were attracted in vitro by supernatants from
cultured lymphoma B cells secreting CCL22 and are involved
in chemotaxis and migration of intratumoral Treg cells to
tumor sites.
In summary, the magnitude of the present study is a conﬁr-
mation for the role played by both intratumoral and peripheral
Treg cell populations in suppressing antitumor immunity.
Our results indicated that selected chemotherapeutic agents
in a mixture (the commonly used CHOP regimen) resulted in a
remarkable impairment of peripheral Treg population mani-
fested by reduced mRNA expression of Foxp3, decreased per-
centage of CD4CD25 double positive cells and impaired
spontaneous molecular release of TGF-b. It remains unknown
however, if chemotherapy selectively deplete peripheral blood
and intratumoral Treg populations or this depletion is a spon-
taneous consequence of the pancytotoxic effect of CHOP com-
ponents on tumor cell populations including Treg cells.
Clariﬁcation of how chemotherapy exerts its immunomodula-
tory effects will aid in the development of better combination
strategies of chemo-immunotherapies in enriching the ﬁeld of
cancer management.Conﬂict of interest
None declared.References
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